The company was founded in March 1951 and listed on the Shanghai Stock Exchange in December 2000. The company has deep professional pharmaceutical experience. Relying on Yunnan's rich plant resources, Kunyao Group has successively developed more than 40 new natural medicine products with advanced standards at home and abroad, including the three major series of artemisia, 37, and Tianma, as well as traditional Chinese medicine and ethnic medicine. At the same time, it inherits fine Chinese medicines, focuses on the 37 industrial chain, and is committed to providing high-quality product services and system solutions for chronic disease management and aging health. The company's industry is pharmaceutical manufacturing. Its business area covers the entire pharmaceutical industry chain, and its core business covers fields such as drug research and development, production and sales, pharmaceutical distribution, and the health industry. The company's core products include Kunyao Hemocalcitone series, artemisinyl ether series, Kunming Traditional Chinese Medicine Shenling Spleen and Stomach Granules, Hepatic Soothing Granules, Incense Stomach Calciferol softgels, sodium hyaluronate injections, etc. The company was selected as the “National Technological Innovation Demonstration Enterprise” assessed by the Ministry of Industry and Information Technology, the “2019 China Pharmaceutical Innovation Enterprise Top 100”, “Top 500 Chinese Enterprise Patents”, and “2022 Chinese Pharmacy Staff Recommendation Rate Brand”, ranked 13th in the “2022 Top 100 Proprietary Chinese Medicine Companies List” and ranked 12th in the “2022 Top 30 Chinese Medicine Listed Companies”. It won the “2023 Best Practice Case for Listed Company Directors” by the China Association of Listed Companies, Securities Daily Honors include the “ESG Pioneer Practitioner” honor, the “Social Responsibility (S) Pioneer Enterprise Award” issued by the Financial Federation and the China Environmental Protection Federation, and the top 100 enterprises in the national pharmaceutical manufacturing industry.